ImageneBio (IMA) Stock Price, News & Analysis

Company Overview

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Key Stats

• Today's Range: $15.03 to $17.70
• 50-Day Range: $13.68 to $17.64
• 52-Week Range: $11.65 to $23.28
• Volume: 79,965 shs
• Average Volume: 13,796 shs
• Market Capitalization: $68.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.50
• Consensus Rating: Moderate Buy

ImageneBio Stock Analysis - MarketRank™

ImageneBio scored higher than 66% of companies evaluated by MarketBeat, and ranked 487th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ImageneBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

ImageneBio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ImageneBio are expected to grow in the coming year, from ($0.91) to ($0.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImageneBio is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImageneBio is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ImageneBio has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.43% of the float of ImageneBio has been sold short.

Short Interest Ratio / Days to Cover

ImageneBio has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImageneBio has recently increased by 11.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImageneBio does not currently pay a dividend.

Dividend Growth

ImageneBio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.43% of the float of ImageneBio has been sold short.

Short Interest Ratio / Days to Cover

ImageneBio has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImageneBio has recently increased by 11.77%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.69

News Sentiment

ImageneBio has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.02 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for ImageneBio this week, compared to 1 article on an average week.

Search Interest

4 people have searched for IMA on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, ImageneBio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,499,893.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 5.94% of the stock of ImageneBio is held by insiders.

Percentage Held by Institutions

75.00% of the stock of ImageneBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMA Stock Analysis - Frequently Asked Questions

How have IMA shares performed this year?

ImageneBio's stock was trading at $19.68 at the beginning of the year. Since then, IMA stock has decreased by 11.1% and is now trading at $17.49.

How were ImageneBio's earnings last quarter?

ImageneBio, Inc. (NASDAQ:IMA) posted its earnings results on Thursday, July, 24th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.08.

When did ImageneBio's stock split?

Shares of ImageneBio reverse split on the morning of Monday, July 28th 2025.The 1-12 reverse split was announced on Friday, July 25th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of ImageneBio?

Shares of IMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 7/24/2025
• Today: 7/31/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMA
• Previous Symbol: NASDAQ:IKNA
• CIK: 1835579
• Web: ikenaoncology.com
• Phone: 857-273-8343
• Fax: N/A
• Employees: 780
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ikena Oncology: $35.50
• High Price Target: $48.00
• Low Price Target: $23.00
• Potential Upside/Downside: +132.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.21
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -23.94%
• Return on Assets: -21.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.52
• Quick Ratio: 13.52

Sales & Book Value

• Annual Sales: $9.16 million
• Price / Sales: 6.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $28.83 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 4,020,000
• Free Float: 3,781,000
• Market Cap: $61.47 million
• Optionable: Not Optionable
• Beta: 0.50